Skip to main content

Table 2 Allele and genotype frequencies of GRIA1 and GRIA3 polymorphisms in Italian patients and controls and association results

From: Common variants in the regulative regions of GRIA1 and GRIA3 receptor genes are associated with migraine susceptibility

Gene

SNP

SAMPLE

N

MAF

SP

MAJOR HOMO

HET

MINOR HOMO

ALLELE P-VALUE

11 vs 12

GENOTYPE P-VALUEs

11 vs 22

11 vs 12+22

ARMITAGE'S TEST -P VALUE

GRIA1

RS548294

C/T

CONTROLS

260

34%

 

125 (48,1%)

102 (39,2%)

33 (12,7%)

     
  

CONT.FEMALE

204

32,3%

 

98 (48%)

80 (39,2%)

26 (12,8%)

     
  

CONT. MALE

56

32,1%

 

27 (48,2%)

22 (39,3%)

7 (12,5%)

     
  

MIGRAINE ALL

244

44,3%

97%

80 (32,8%)

112 (45,9%)

52 (21,3%)

0,00009 (0,002*)

(OR 1,7/CI 1,2-2,1)

0,006 (NS*)

(OR 1,7/CI 1,1-2,5)

0,0005 (0,01*)

(OR 2,4/CI 1,5-4,1)

0,0005 (0,01*)

(OR 1,9/CI 1,3-2,7)

0,0002 (0,005*)

  

MA

135

42,6%

80%

52 (38,5%)

51 (37,8%)

32 (23,7%)

0,004 (NS*)

(OR 1,6/CI 1,1-2,1)

0,4 (NS*)

0,004 (NS*)

(OR 2,3/CI 1,3-4,1)

0,07 (NS*)

0,007 (NS*)

  

MO

109

46,3%

78%

28 (25,7%)

61 (56%)

20 (18,3%)

0,0003 (0,008*)

(OR 1,8/CI 1,3-2,5)

0,0001 (0,003*)

(OR 2,6/CI 1,6-4,5)

0,003 (NS*)

(OR 2,7/CI 1,3-5,3)

0,00007 (0,002*)

(OR 2,7/CI 1,6-4,3)

0,0004 (0,01*)

  

MIG. FEMALE

188

44,1%

90%

63 (33,5%)

84 (44,7%)

41 (21,5%)

0,0007 (0,02*)

(OR 1,6/CI 1,2-2,2)

0,02 (NS*)

(OR 1,6/CI 1,0-2,5)

0,002 (0,05*)

(OR 2,4/CI 1,3-4,4)

0,003 (NS*)

(OR 1,8/CI 1,2-2,7)

0,001 (0,03*)

  

MIG. MALE

56

41%

38%

19 (34%)

28 (50%)

9 (16%)

0,1

0,1

0,3

0,1

0,1

 

RS2195450

G/A

CONTROLS

260

34,2%

 

128 (49,2%)

86 (33%)

46 (17,8%)

     
  

CONT. FEMALE

204

34,5%

 

95 (46,6%)

77 (37,7%)

32 (15,7%)

     
  

CONT. MALE

56

33%

 

30 (53,6%)

15 (26,7%)

11 (19,6%)

     
  

MIGRAINE ALL

244

45,5%

97%

98 (40,1%)

70 (28,7%)

76 (31,2%)

0,0002 (0,005*)

(OR 1,6/CI 1,2-2,0)

0,7

0,0007 (0,02*)

(OR 2,1/CI 1,3-3,3)

0,04 (NS*)

(OR 1,4/CI 1-2)

0,001 (0,03*)

  

MA

135

50%

80%

51 (38%)

33 (24%)

51 (38%)

0,00002 (0,0005*)

(OR 1,9/CI 1,4-2,5)

0,8

0,00008 (0,002*)

(OR 2,7/CI 1,6-4,6)

0,03 (NS*)

(OR 1,6/CI 1,0-2,4)

0,0002 (0,005*)

  

MO

109

39%

78%

47 (43,2%)

39 (35,7%)

23 (21,1%)

0,2

0,4

0,3

0,2

0,2

  

MIG. FEMALE

188

42,3%

90%

83 (44,1%)

51 (27,1%)

54 (28,8%)

0,02 (NS*)

(OR 1,3/CI 1-1,8)

0,2

0,01 (NS*)

(OR 1,9/CI 1,1-3,2)

0,6

0,05 (NS*)

  

MIG. MALE

56

53,5%

38%

17 (30,3%)

18 (32,1%)

21 (37,5%)

0,001 (0,03*)

(OR 2,3/CI 1,3-4)

0,1

0,01 (NS*)

(OR 3,3/CI 1,3-8,6)

0,01 (NS*)

(OR 2,6/CI 1,2-5,7)

0,008 (NS*)

GRIA3

RS3761555

T/C

CONTROLS

260

22,3%

 

170 (65,3%)

64 (24,6%)

26 (10,1%)

     
  

CONT.FEMALE

204

23,5%

 

124 (60,7%)

64 (31,3%)

16 (8%)

     
  

CONT. MALE

56

17,9%

 

46 (82,1%)

 

10 (17,9%)

     
  

MIG. FEM.ALL

188

34,6%

93%

83 (44,1%)

80 (42,5%)

25 (13,4%)

0,0006 (0,01*)

(OR 1,7/CI 1,2-2,3)

0,004 (NS*)

(OR 1,8/CI 1,2-2,8)

0,01 (NS*)

(OR 2,3/CI 1,1-4,6)

0,0009 (0,02*)

(OR 1,9/CI 1,3-2,9)

0,001 (0,003*)

  

MA-FEMALE

112

38%

84%

44 (39,3%)

51 (45,5%)

17 (15,2%)

0,0001 (0,003*)

(OR 2/CI 1,4-2,8)

0,001 (0,03*)

(OR 2,3/CI 1,3-3,7)

0,003 (NS*)

(OR 3/CI 1,4-6,4)

0,0002 (0,005*)

(OR 2,4/CI 1,5-3,8)

0,0002 (0,005*)

  

MO-FEMALE

76

30%

73%

38 (50%)

30 (39,5%)

8 (10,5%)

0,1

0,1

0,2

0,1

0,1

  

MIG. MALE

56

 

40%

36 (64,5%)

 

20 (35,5%)

0,03 (NS*)

(OR 2,46/CI 1,07-5,6)

    
  1. p-values for allele and genotype distributions are showed. Minor allele frequency is indicated as MAF. To assess the dosage effect of possessing zero, one or two copies of the risk allele (i.e. an additive effect), the Armitage test for linear trend in proportions was performed on the genotype frequency data. Genetic risk magnitudes (effect size) were estimated by calculating odds ratio (ORs) with 95% confidence intervals (95% CI). All statistical tests were two-tailed. Statistical significance was defined as a p value lower than 0.05. NS, not significant after Bonferroni correction, * Pvalues after Bonferroni correction. The percentages of genotype and allele frequency are in parentheses. The Pvalues less than 0.05 are in bold. Statistical power (SP) was calculated for all groups and subgroups analyzed.
Back to article page

BMC Medical Genetics

ISSN: 1471-2350

Contact us